Processa pharmaceuticals announces first patient dosed in the 300 mg dose group with next generation chemotherapy-capecitabine

Hanover, md, march 17, 2023 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a developer of next generation chemotherapies (ngcs), today announced that the company has dosed the first patient in its ngc-capecitabine (combination of pcs6422 and capecitabine) 300 mg dose group. the processa ngcs already have clinical evidence to support their safety and efficacy while they target patients who need better treatment options for their cancer in order to improve survival and/or quality of life.
PCSA Ratings Summary
PCSA Quant Ranking